754
Views
57
CrossRef citations to date
0
Altmetric
Original Research

Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals

, , , , , & show all
Pages 5733-5744 | Published online: 12 Nov 2012

References

  • GassmannPListMSchweitzerASuckerHHydrosols-alternatives for the parenteral application of poorly water soluble drugsEur J Pharm Biopharm19944026472
  • MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the futureAdv Drug Deliv Rev200147131911251242
  • DolencAKristlJBaumgartnerSPlaninsekOAdvantages of celecoxib nanosuspension formulation and transformation into tabletsInt J Pharm200937612220421219426794
  • JinnoJKamadaNMiyakeMEffect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogsJ Control Release20061111/2566416410029
  • MüllerRHPetersKNanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction techniqueInt J Pharm19981602229237
  • DongYNgWKShenSKimSTanRBHPreparation and characterization of spironolactone nanoparticles by antisolvent precipitationInt J Pharm20093751/2848819481693
  • KesisoglouFPanmaiSWuYNanosizing – oral formulation development and biopharmaceutical evaluationAdv Drug Deliv Rev200759763164417601629
  • MauludinRMüllerRHKeckCMKinetic solubility and dissolution velocity of rutin nanocrystalsEur J Pharm Sci2009364/550251019130880
  • MosharrafMNyströmCThe effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugsInt J Pharm19951221/23547
  • WuWNancollasGHA new understanding of the relationship between solubility and particle sizeJ Solution Chem1998276521531
  • KippJEThe role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugsInt J Pharm20042841/210912215454302
  • NoyesAAWhitneyWRThe rate of solution of solid substances in their own solutionsJ Am Chem Soc18971912930934
  • DokoumetzidisAMacherasPA century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification SystemInt J Pharm2006321111116920290
  • BabuVRAreefullaSMallikarjunVSolubility and dissolution enhancement: an overviewJ Pharm Res201031141145
  • GhoshIBoseSVippaguntaRHarmonFNanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growthInt J Pharm20114091/226026821371540
  • KocbekPBaumgartnerSKristlJPreparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugsInt J Pharm20063121/217918616469459
  • RaoGCKumarMSMathivananNRaoMENanosuspensions as the most promising approach in nanoparticulate drug delivery systemsPharmazie20045915914964413
  • RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov20043978579615340388
  • MatteucciMEHotzeMAJohnstonKPWilliamsRODrug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilizationLangmuir200622218951895917014140
  • ZhangJYShenZGZhongJPreparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactantsInt J Pharm20063231/215316016828244
  • ZhangXXiaQGuNPreparation of all-trans retinoic acid nanosuspensions using a modified precipitation methodDrug Dev Ind Pharm200632785786316908423
  • BabaKPudavarHERoyINew method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drugMol Pharm20074228929717266331
  • WangFSunJDengYHRelationship between particle size and solubility of coenzyme Q10 nanosuspensionsJ Shenyang Pharm Univ20102712933939
  • SunJDengYHMaYLHanJEquilibrium solubility of naked nanocrystals is not related to particle sizeJ Shenyang Pharm Univ20112808585593
  • AnkolaDViswanadBBhardwajVRamaraoPKumarMDevelopment of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?Eur J Pharm Biopharm200767236136917452099
  • SheridanPLBucktonGStoreyDEThe extent of errors associated with contact angles II. Factors affecting data obtained using a Wilhelmy plate technique for powdersInt J Pharm19941092155171
  • AnderbergEKBisratMNyströmCPhysicochemical aspects of drug release. VII. The effect of surfactant concentration and drug particle size on solubility and dissolution rate of felodipine, a sparingly soluble drugInt J Pharm1988471/36777
  • HengDCutlerDJChanHKYunJRaperJAWhat is a suitable dissolution method for drug nanoparticles?Pharm Res20082571696170118320295
  • Van EerdenbrughBVermantJMartensJASolubility increases associated with crystalline drug nanoparticles: methodologies and significanceMol Pharm201016718581870
  • BergstromCAWassvikCMJohanssonKHubatschIPoorly soluble marketed drugs display solvation limited solubilityJ Med Chem200750235858586217929794
  • HecqJDeleersMFanaraDVranckxHAmighiKPreparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipineInt J Pharm20052991/216717715996838
  • PalamakulaASolimanMKhanMMRegional permeability of coenzyme Q10 in isolated rat gastrointestinal tractsPharmazie200560321221415801676